Treatment of PSC in Children with Concomitant Autoimmune Hepatitis

Primary sclerosing cholangitis (PSC) in the pediatric population can present differently than in adults. When autoimmune hepatitis occurs alongside PSC, the clinical picture and therapeutic strategy shift meaningfully.

Clinical scenario: Children with primary sclerosing cholangitis and concomitant autoimmune hepatitis — sometimes described under the term "autoimmune sclerosing cholangitis" — tend to show higher serum aminotransferase levels and a higher rate of sclerosing cholangitis features. Workup in pediatric PSC should include targeted efforts to identify this co-occurring condition, as its presence calls for a distinct therapeutic approach.

When autoimmune hepatitis is identified alongside PSC in a child, the management approach may incorporate immunomodulatory therapy — the full structured regimen specifies the options and their sequence.

Instant Access to Structured Evidence-Based Regimens

References

Furthermore, PSC in children is more often associated with higher serum aminotransferase levels and concomitant autoimmune hepatitis, and sclerosing cholangitis is a more common phenomenon, leading to the use of the term "autoimmune sclerosing cholangitis."

In summary, pediatric PSC may have a different clinical presentation than in adults and the workup should include efforts to identify concomitant autoimmune hepatitis, which may lead to a different therapeutic approach (i.e., corticosteroids or immunosuppressive medications).

DOI: 10.1038/ajg.2015.112

View source ↗